This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ford, S. L.
Right arrow Articles by Stein, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ford, S. L.
Right arrow Articles by Stein, D. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2005, p. 467-469, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.467-469.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Effect of Antacids and Ranitidine on the Single-Dose Pharmacokinetics of Fosamprenavir

Susan L. Ford,1* Mary B. Wire,1 Yu Lou,1 Katherine L. Baker,1 and Daniel S. Stein2

GlaxoSmithKline, Research Triangle Park, North Carolina,1 Aventis Pharmaceuticals, Bridgewater, New Jersey2

Received 2 June 2004/ Returned for modification 11 July 2004/ Accepted 15 September 2004

Single doses of MAALOX TC and ranitidine were administered separately with 1,400 mg of fosamprenavir (FPV). MAALOX TC decreased the area under the concentration-time curve from 0 to 24 h (AUC0-24) for plasma amprenavir (APV) by 18% and the maximum concentration of drug in serum (Cmax) by 35%; the plasma APV concentration at 12 h (C12) increased by 14%. Ranitidine at 300 mg decreased the AUC0-24 for plasma APV by 30% and Cmax by 51%; C12 was unchanged. FPV may be coadministered with antacids without concern and without separation in dosing; however, caution is recommended when FPV is coadministered with histamine2- receptor antagonists or proton pump inhibitors.

* Corresponding author. Mailing address: GlaxoSmithKline, 5 Moore Dr., Research Triangle Park, NC 27709. Phone: (919) 483-0392. Fax: (919) 483-6380. E-mail: susan.l.ford{at}gsk.com.

Antimicrobial Agents and Chemotherapy, January 2005, p. 467-469, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.467-469.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Klein, C. E., Chiu, Y.-L., Cai, Y., Beck, K., King, K. R., Causemaker, S. J., Doan, T., Esslinger, H.-U., Podsadecki, T. J., Hanna, G. J. (2008). Effects of Acid-Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir-Boosted Atazanavir. J Clin Pharmacol 48: 553-562 [Abstract] [Full Text]  
  • Tappouni, H. L., Rublein, J. C., Donovan, B. J., Hollowell, S. B., Tien, H.-C., Min, S. S., Theodore, D., Rezk, N. L., Smith, P. C., Tallman, M. N., Raasch, R. H., Kashuba, A. D. M. (2008). Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. Am J Health Syst Pharm 65: 422-428 [Abstract] [Full Text]  
  • Sekar, V. J., Lefebvre, E., De Paepe, E., De Marez, T., De Pauw, M., Parys, W., Hoetelmans, R. M. W. (2007). Pharmacokinetic Interaction between Darunavir Boosted with Ritonavir and Omeprazole or Ranitidine in Human Immunodeficiency Virus-Negative Healthy Volunteers. Antimicrob. Agents Chemother. 51: 958-961 [Abstract] [Full Text]  
  • Fulco, P. P., Vora, U. B, Bearman, G. M. (2006). Acid Suppressive Therapy and the Effects on Protease Inhibitors. The Annals of Pharmacotherapy 40: 1974-1983 [Abstract] [Full Text]  
  • Winston, A., Boffito, M. (2005). The management of HIV-1 protease inhibitor pharmacokinetic interactions. J Antimicrob Chemother 56: 1-5 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»